Johnson & Johnson (J&J) announced today that it has received CE-mark approvals for its Cereglide 42 and Cereglide 57 aspiration catheters, noting in a press release that—together with Cereglide 71 and the Innerglide 7 delivery aid—these additions expand J&J’s MedTech Stroke Solutions portfolio in the Europe, Middle East and Africa (EMEA) region.
“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” said Christian Cuzick, worldwide president of neurovascular at J&J MedTech. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.”
The Cereglide 42 and Cereglide 57 aspiration catheters are single-lumen, variable-stiffness catheters, each of which has a hydrophilic coating to improve lubricity during navigation and includes a radiopaque marker on the distal tip for fluoroscopic visualisation, according to J&J.
The Cereglide 71 aspiration system is composed of the Cereglide 71 aspiration catheter—which shares the aforementioned qualities associated with smaller Cereglide catheter sizes—and the Innerglide 7 delivery aid, which is designed to facilitate delivery of Cereglide 71 to selected neurovascular vessels.
“With the addition of Cereglide 42, Cereglide 57 and Innerglide 7, we complete our aspiration portfolio, and provide physicians with a comprehensive solution across varied anatomies and clot locations,” added Alistair Stewart, the company’s business unit head for neurovascular in the EMEA region. “Grounded in our heritage of stroke and clot science, and complemented by Embotrap III and Nimbus, this portfolio reinforces our commitment to helping clinicians optimise outcomes for patients with stroke.”
